Literature DB >> 14557638

Human immunodeficiency virus type 1 escape from RNA interference.

Daniel Boden1, Oliver Pusch, Frederick Lee, Lynne Tucker, Bharat Ramratnam.   

Abstract

Sequence-specific degradation of mRNA by short interfering RNA (siRNA) allows the selective inhibition of viral proteins that are critical for human immunodeficiency virus type 1 (HIV-1) replication. The aim of this study was to characterize the potency and durability of virus-specific RNA interference (RNAi) in cell lines that stably express short hairpin RNA (shRNA) targeting the HIV-1 transactivator protein gene tat. We found that the antiviral activity of tat shRNA was abolished due to the emergence of viral quasispecies harboring a point mutation in the shRNA target region. Our results suggest that, in order for RNAi to durably suppress HIV-1 replication, it may be necessary to target highly conserved regions of the viral genome. Alternatively, similar to present antiviral drug therapy paradigms, DNA constructs expressing multiple siRNAs need to be developed that target different regions of the viral genome, thereby reducing the probability of generating escape mutants.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14557638      PMCID: PMC229317          DOI: 10.1128/jvi.77.21.11531-11535.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  11 in total

1.  siRNA-directed inhibition of HIV-1 infection.

Authors:  Carl D Novina; Michael F Murray; Derek M Dykxhoorn; Paul J Beresford; Jonathan Riess; Sang-Kyung Lee; Ronald G Collman; Judy Lieberman; Premlata Shankar; Phillip A Sharp
Journal:  Nat Med       Date:  2002-06-03       Impact factor: 53.440

2.  Short interfering RNA confers intracellular antiviral immunity in human cells.

Authors:  Leonid Gitlin; Sveta Karelsky; Raul Andino
Journal:  Nature       Date:  2002-06-26       Impact factor: 49.962

3.  Tolerance for mutations and chemical modifications in a siRNA.

Authors:  Mohammed Amarzguioui; Torgeir Holen; Eshrat Babaie; Hans Prydz
Journal:  Nucleic Acids Res       Date:  2003-01-15       Impact factor: 16.971

4.  Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis.

Authors:  B Ramratnam; S Bonhoeffer; J Binley; A Hurley; L Zhang; J E Mittler; M Markowitz; J P Moore; A S Perelson; D D Ho
Journal:  Lancet       Date:  1999-11-20       Impact factor: 79.321

5.  Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells.

Authors:  Nan Sook Lee; Taikoh Dohjima; Gerhard Bauer; Haitang Li; Ming-Jie Li; Ali Ehsani; Paul Salvaterra; John Rossi
Journal:  Nat Biotechnol       Date:  2002-05       Impact factor: 54.908

6.  RNA interference directed against viral and cellular targets inhibits human immunodeficiency Virus Type 1 replication.

Authors:  Rama M Surabhi; Richard B Gaynor
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

7.  Stable suppression of tumorigenicity by virus-mediated RNA interference.

Authors:  Thijn R Brummelkamp; René Bernards; Reuven Agami
Journal:  Cancer Cell       Date:  2002-09       Impact factor: 31.743

8.  Double-stranded nef RNA interferes with human immunodeficiency virus type 1 replication.

Authors:  Takuya Yamamoto; Shinya Omoto; Masaaki Mizuguchi; Hajime Mizukami; Harumi Okuyama; Noriko Okada; Nitin K Saksena; Ebiamadon A Brisibe; Kaori Otake; Yoichi R Fuji
Journal:  Microbiol Immunol       Date:  2002       Impact factor: 1.955

9.  Inhibition of HIV-1 infection by small interfering RNA-mediated RNA interference.

Authors:  John Capodici; Katalin Karikó; Drew Weissman
Journal:  J Immunol       Date:  2002-11-01       Impact factor: 5.422

10.  Modulation of HIV-1 replication by RNA interference.

Authors:  Jean-Marc Jacque; Karine Triques; Mario Stevenson
Journal:  Nature       Date:  2002-06-26       Impact factor: 69.504

View more
  171 in total

1.  Nucleotide sequence homology requirements of HIV-1-specific short hairpin RNA.

Authors:  Oliver Pusch; Daniel Boden; Rebecca Silbermann; Fred Lee; Lynne Tucker; Bharat Ramratnam
Journal:  Nucleic Acids Res       Date:  2003-11-15       Impact factor: 16.971

2.  Enhanced gene silencing of HIV-1 specific siRNA using microRNA designed hairpins.

Authors:  Daniel Boden; Oliver Pusch; Rebecca Silbermann; Fred Lee; Lynne Tucker; Bharat Ramratnam
Journal:  Nucleic Acids Res       Date:  2004-02-13       Impact factor: 16.971

3.  RNA interference against animal viruses: how morbilliviruses generate extended diversity to escape small interfering RNA control.

Authors:  Carine L Holz; Emmanuel Albina; Cécile Minet; Renaud Lancelot; Olivier Kwiatek; Geneviève Libeau; Renata Servan de Almeida
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

4.  HIV develops indirect cross-resistance to combinatorial RNAi targeting two distinct and spatially distant sites.

Authors:  Priya S Shah; Nhung P Pham; David V Schaffer
Journal:  Mol Ther       Date:  2012-01-31       Impact factor: 11.454

5.  Dual-targeting siRNAs.

Authors:  Katrin Tiemann; Britta Höhn; Ali Ehsani; Stephen J Forman; John J Rossi; Pål Saetrom
Journal:  RNA       Date:  2010-04-21       Impact factor: 4.942

Review 6.  HIV-1 evolution: frustrating therapies, but disclosing molecular mechanisms.

Authors:  Atze T Das; Ben Berkhout
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2010-06-27       Impact factor: 6.237

7.  Titers of lentiviral vectors encoding shRNAs and miRNAs are reduced by different mechanisms that require distinct repair strategies.

Authors:  Ying Poi Liu; Monique A Vink; Jan-Tinus Westerink; Eva Ramirez de Arellano; Pavlina Konstantinova; Olivier Ter Brake; Ben Berkhout
Journal:  RNA       Date:  2010-05-24       Impact factor: 4.942

Review 8.  Current progress in the development of RNAi-based therapeutics for HIV-1.

Authors:  J Zhou; J J Rossi
Journal:  Gene Ther       Date:  2011-09-29       Impact factor: 5.250

9.  CRISPR-mediated Activation of Latent HIV-1 Expression.

Authors:  Prajit Limsirichai; Thomas Gaj; David V Schaffer
Journal:  Mol Ther       Date:  2015-11-26       Impact factor: 11.454

10.  Small interfering RNA targeted to hepatitis C virus 5' nontranslated region exerts potent antiviral effect.

Authors:  Tatsuo Kanda; Robert Steele; Ranjit Ray; Ratna B Ray
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.